- Home
- OVID vs ATOS Comparison
OVID vs ATOS Comparison
Compare OVID & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- ATOS
- Stock Information
- Founded
- OVID 2014
- ATOS 2009
- Country
- OVID United States
- ATOS United States
- Employees
- OVID N/A
- ATOS N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- ATOS Health Care
- Exchange
- OVID Nasdaq
- ATOS Nasdaq
- Market Cap
- OVID 117.3M
- ATOS 106.9M
- IPO Year
- OVID 2017
- ATOS 2012
- Fundamental
- Price
- OVID $1.34
- ATOS $0.83
- Analyst Decision
- OVID Strong Buy
- ATOS Strong Buy
- Analyst Count
- OVID 4
- ATOS 3
- Target Price
- OVID $3.13
- ATOS $6.25
- AVG Volume (30 Days)
- OVID 1.5M
- ATOS 589.7K
- Earning Date
- OVID 11-12-2025
- ATOS 11-12-2025
- Dividend Yield
- OVID N/A
- ATOS N/A
- EPS Growth
- OVID N/A
- ATOS N/A
- EPS
- OVID N/A
- ATOS N/A
- Revenue
- OVID $6,610,000.00
- ATOS N/A
- Revenue This Year
- OVID $1,081.80
- ATOS N/A
- Revenue Next Year
- OVID N/A
- ATOS N/A
- P/E Ratio
- OVID N/A
- ATOS N/A
- Revenue Growth
- OVID 945.89
- ATOS N/A
- 52 Week Low
- OVID $0.24
- ATOS $0.55
- 52 Week High
- OVID $2.01
- ATOS $1.41
- Technical
- Relative Strength Index (RSI)
- OVID 45.93
- ATOS 38.22
- Support Level
- OVID $1.24
- ATOS $0.77
- Resistance Level
- OVID $1.39
- ATOS $0.88
- Average True Range (ATR)
- OVID 0.10
- ATOS 0.05
- MACD
- OVID -0.02
- ATOS -0.01
- Stochastic Oscillator
- OVID 44.29
- ATOS 26.71
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.